GlassScriptPhysician profile
Soraj Arora
NPI 1871571208
$8,992.98
in general payments reported to CMS, 2019-2025
50 companies · $1,015 in 2025
The $1,015 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,435 · 2020: $1,236 · 2021: $1,605 · 2022: $1,630 · 2023: $1,318 · 2024: $755 · 2025: $1,015.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,088.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,087.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,490.65 | 2019-2025 | Repatha, Repatha, Otezla |
| Vanda Pharmaceuticals INC. | $804.19 | 2020-2023 | Hetlioz |
| Astrazeneca Pharmaceuticals LP | $770.88 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Nestle Healthcare Nutrition INC. | $758.59 | 2020-2023 | |
| Novo Nordisk INC | $753.09 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $635.17 | 2020-2025 | Viberzi, Linzess |
| Sanofi-Aventis U.S. LLC | $411.51 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $319.04 | 2020-2024 | Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $318.20 | 2019-2023 | Xifaxan, Trulance |
| Lilly USA, LLC | $272.49 | 2019-2023 | Emgality |
| Ardelyx, INC. | $248.87 | 2024-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $210.74 | 2019-2025 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $168.61 | 2021-2025 | |
| Allergan, INC. | $138.26 | 2019 | |
| Ethicon INC. | $130.76 | 2023 | Monarch Platform |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Soraj Arora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.